Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-18T22:22:04.249Z Has data issue: false hasContentIssue false

From polipharmacy to monotheraphy a case about schizoaffective disorder

Published online by Cambridge University Press:  23 March 2020

S.F. Salonia
Affiliation:
CSM Yecla, Psychiatry, Yecla, Spain
P.E. Asensio Pascual
Affiliation:
CSM Yecla, Psychiatry, Yecla, Spain
B. Pérez Molina
Affiliation:
CSM Yecla, Psychiatry, Yecla, Spain
A.M. García Herrero
Affiliation:
CSM Yecla, Psychiatry, Yecla, Spain
M.D.C. Martinez Tomás
Affiliation:
CSM Yecla, Psychiatry, Yecla, Spain
J. Martinez Martinez
Affiliation:
CSM Yecla, Nursing, Yecla, Spain
Á.A. Maroto Hernández
Affiliation:
CSM Yecla, Nursing, Yecla, Spain
A.M. Gea Jimenez
Affiliation:
CSM Yecla, Nursing, Yecla, Spain
F.J. Sanchís Lledó
Affiliation:
CSM Yecla, Psychology, Yecla, Spain
M. Infante Sánchez de Lugarnuevo
Affiliation:
CSM Yecla, Psychology, Yecla, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The aim of the present poster is to describe an initial complex case of schizoaffective disorder with other clinical adverse conditions (metabolic disorders) in a young adult male, which gradually went into a positive treatment way from polipharmacy to monoteraphy. His psychiatric history started when he was 25-year-old, he was diagnosed of heroine dependence, hypercholesterolemia and hypertrigliceridemia. In 2000 he had a suicide attempt in a context of depressive mood and delusions. He needed a psychiatric hospitalization for the first time in his life and he received anti-psychotics for the first time too. Drug abuse was detected in that hospitalization (cannabis and alcohol). In 2001 was diagnosed of paranoid schizophrenia. In 2007 the diagnosis was modified to schizoaffective disorder and also was detected high blood pressure, Diabetes Mellitus II and overweight. From 2007 to the present he passed from a scheme treatment composed by four or more psychotropic drugs to monotherapy (only one psychotropic drug, an anti-psychotic), he stayed clinically stable and all his metabolic parameters remained equal or improved.

Disclosure of interest

Janssen-Cilag research study.

Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.